Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia

Article English OPEN
Smith, Toby ; Maidment, Ian ; Hebding, Jennifer ; Madzima, Tairo ; Cheater, Francine ; Cross, Jane ; Poland, Fiona ; White, Jacqueline ; Young, John ; Fox, Chris (2014)

Objectives: dementia is a debilitating condition characterised by global loss of cognitive and intellectual functioning, which reduces social and occupational performance. This population frequently presents with medical co-morbidities such as hypertension, cardiovascular disease and diabetes. The CONSORT statement outlines recommended guidance on reporting of participant characteristics in clinical trials. It is, however, unclear how much these are adhered to in trials assessing people with dementia. This paper assesses the reporting of medical co-morbidities and prescribed medications for people with dementia within randomised controlled trial (RCT) reports. Design: a systematic review of the published literature from the databases AMED, CINAHL, MEDLINE, EMBASE and the Cochrane Clinical Trial Registry from 1 January 1997 to 9 January 2014 was undertaken in order to identify RCTs detailing baseline medical co-morbidities and prescribed medications . Eligible studies were appraised using the Critical Appraisal Skills Programme (CASP) RCT appraisal tool, and descriptive statistical analyses were calculated to determine point prevalence. Results: nine trials, including 1474 people with dementia, were identified presenting medical co-morbidity data. These indicated neurological disorders ( prevalence 91%), vascular disorders (prevalence 91%), cardiac disorders ( prevalence 74%) and ischaemic cerebrovascular disease ( prevalence 53%) were most frequently seen. Conclusions: published RCTs poorly report medical co-morbidities and medications for people with dementia. Future trials should include the report of these items to allow interpretation of whether the results are generalisable to frailer older populations.
  • References (21)
    21 references, page 1 of 3

    1. Thomas K, Stobbart Rowlands M, Giles L. Meeting the prime minister's dementia challenge: improving care and increasing acp discussions for people with dementia following the gold standards framework (gsf) dementia care training programme. BMJ Support Palliat Care 2013; 3: 288-9.

    2. Helvik AS, Engedal K, Benth JS, Selbaek G. A 52 month follow-up of functional decline in nursing home residents - degree of dementia contributes. BMC Geriatr 2014; 14: 45.

    3. Healthcare at Home. Understanding out of hospital dementia care report. 2011. Accessed on 16th April 2014. Available at:

    4. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152: 726-32.

    5. Critical Appraisal Skills Programme - Randomised Controlled Trial Tool. Accessed on 3rd January 2014. Available at:!casp-tools-checklists/c18f8

    6. Iwasaki K, Kobayashi S, Chimura Y et al. A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine "ba wei di huang wan" in the treatment of dementia. J Am Geriatr Soc; 52:1518-21.

    7. Ihl R, Tribanek M, Bachinskaya N. Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial. J Neurol Sci 2010; 299: 184-7.

    8. Doody RS, Gavrilova SI, Sano M et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008; 372: 207-15.

    9. Moraes W, Poyares D, Sukys-Claudino L, Guilleminault C, Tufik S. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. Chest 2008; 133: 677-83.

    10. Scarpini E, Bruno G, Zappalà G et al. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. J Alzheimers Dis 2011; 26: 211-20.

  • Metrics
    No metrics available
Share - Bookmark